Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Immunicum AB has, as previously announced, implemented a directed issue to a number of institutional and private investors. The newly implemented share issue has entailed a change in number of shares and votes in the Company.
Harpoon initiated a Phase I trial for its lead candidate for prostate cancer earlier this summer.
Boston Scientific is exercising its option to buy the remaining shares of Santa Rosa, Calif.-based Millipede. The original deal was entered into in January 2018, when Boston Scientific acquired $90 million shares with the option to buy the remaining $325 million, which the company did yesterday.
Most of the IPOs that occurred in the Bay State have been well-documented by BioSpace. But, with a new calendar year upon us, it’s a good idea to look back at a banner year of capitalization that may not repeat when January rolls around. With the turn of the year only days away, BioSpace takes a look at some of the key Massachusetts-based IPOs.
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle.
Gossamer Bio, headquartered in San Diego, announced plans for its initial public offering (IPO) just before Christmas.
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
Turning an existing partner into a wholly owned subsidiary, Novartis is acquiring CellforCure from biotechnology group LFB for an undisclosed figure.
Endocyte, Inc. today announced that at its Special Meeting of Stockholders held earlier today, Endocyte’s stockholders approved the adoption of the merger agreement pursuant to which Novartis AG will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.
Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.